Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring | WHS 2021 Virtual Meeting
May 06, 2021 17:23 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2021 Financial Results on May 10, 2021
April 12, 2021 07:30 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Holdings Inc. Reports Fourth Quarter and Fiscal Year 2020 Financial Results; Introduces Fiscal Year 2021 Guidance
March 16, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
Organogenesis Appoints David C. Francisco as Chief Financial Officer
February 16, 2021 07:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in February and March
February 09, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 16, 2021
February 08, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee Osteoarthritis
January 14, 2021 07:00 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of...
Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
January 13, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the Knee
January 11, 2021 09:01 ET
|
Organogenesis Holdings Inc.
FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis RMAT Designation Enables Closer...
Organogenesis Holdings Inc. to Participate in the ICR Conference 2021
January 05, 2021 16:05 ET
|
Organogenesis Holdings Inc.
CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...